Celldex Therapeutics Quote - CLDX

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

27.21

Bid

27.19

Offer

27.23

Volume

325,368

26.19 Day's Range 28.65

22.9291 52 Week Range 53.18

Market Cap

1.805B

Previous Close

26.22

Open

26.28

Last Trade

27.205

Last Trade Time

05:47:25

Financial Volume

US$ 9,062,694

VWAP

27.8537

Average Volume (3m)

1,197,305

Shares Outstanding

66,344,236

Dividend Yield

PE Ratio

-12.86

Earnings Per Share (EPS)

-2.13

Revenue

6.88M

Net Profit

-141.43M

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung c... Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527. Show more

Sector

In Vitro,in Vivo Diagnostics

Industry

In Vitro,in Vivo Diagnostics

Website

www.celldex.com

Headquarters

Wilmington, Delaware, USA

Founded

Celldex Therapeutics Inc is listed in the In Vitro,in Vivo Diagnostics sector of the NASDAQ with ticker CLDX. The last closing price for Celldex Therapeutics was US$26.22. Over the last year, Celldex Therapeutics shares have traded in a share price range of US$ 22.9291 to US$ 53.18.

Celldex Therapeutics currently has 66,344,236 shares in issue. The market capitalisation of Celldex Therapeutics is US$1.74 billion. Celldex Therapeutics has a price to earnings ratio (PE ratio) of -12.86.

Form 4 - Statement of changes in beneficial ownership of securities

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

HAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 1a study of CDX-622 in...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.22	0.815116709893	26.99	28.65	26.19	649277	27.3148007	CS
4	1.21	4.65384615385	26	28.65	22.9291	1051686	26.40709441	CS
12	-14.58	-34.8887293611	41.79	47	22.9291	1197305	31.09518171	CS
26	-5.68	-17.2696868349	32.89	47	22.9291	926854	33.54265591	CS
52	-4.94	-15.365474339	32.15	53.18	22.9291	854358	36.93765176	CS
156	-8.69	-24.2061281337	35.9	53.18	19.85	677969	34.27669293	CS
260	24.67	971.25984252	2.54	57.2	1.5	764348	26.49704667	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CYCNCyclerion Therapeutics Inc	US$ 7.2136 (348.05%)	115.72M
SMXSMX Security Matters Public Company	US$ 0.512549 (163.12%)	457.13M
CNEYCN Energy Group Inc	US$ 0.593026 (87.90%)	155.23M
SRMSRM Entertainment Inc	US$ 1.1208 (77.88%)	133.89M
HTOOFusion Fuel Green PLC	US$ 0.559 (75.79%)	267.09M
RLMDRelmada Therapeutics Inc	US$ 0.643 (-76.79%)	14.06M
MIGIMawson Infrastructure Group Inc	US$ 0.8422 (-55.91%)	10.9M
MONDMondee Holdings Inc	US$ 0.1998 (-32.29%)	2.58M
ORISOriental Rise Holdings Ltd	US$ 8.48 (-29.04%)	507.23k
FGLFounder Group Limited	US$ 2.95 (-27.70%)	9.79M
SMXSMX Security Matters Public Company	US$ 0.512549 (163.12%)	457.13M
SVMHSRIVARU Holding Ltd	US$ 0.0267 (21.36%)	438.3M
HTOOFusion Fuel Green PLC	US$ 0.559 (75.79%)	267.09M
CNEYCN Energy Group Inc	US$ 0.593026 (87.90%)	155.23M
SRMSRM Entertainment Inc	US$ 1.1208 (77.88%)	133.89M